AeroPath Systems LLC Competitors

Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. We make biology measurable at its most fundamental level, delivering earlier insight when it matters most. Across discovery and clinical applications, Quanterix empowers scientists and healthcare providers to improve patients’ lives through detection and understanding of disease. Learn more at www.quanterix.com.

PathAI's mission is to improve patient outcomes with AI-powered pathology. Our platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine learning. We are a company of diverse employees with a wide range of backgrounds and experiences. Our world class team is passionate about solving challenging problems and making a huge impact. Our office is located in the heart of Fenway. PathAI was recently voted one of BBJ's Best Places to Work!

From discovery to diagnosis, the HALO® suite supports the full digital pathology journey. Indica Labs delivers AI-powered solutions spanning life science research, translational science, pharmaceutical development, companion diagnostics, and clinical deployment. Today, HALO has surpassed 3,000 deployments across 35 countries and six continents, supporting all 20 of the world’s top pharmaceutical companies and research cited in more than 2,600 peer-reviewed publications. That global research footprint is increasingly translating into clinical adoption, with HALO AP® clinical revenue growing 260% since 2023 and recurring clinical revenue increasing 200% year-over-year in 2025. From HALO®, HALO AI, and HALO Link to HALO AP® (CE-IVDR marked) and HALO AP Dx (FDA 510k cleared), one connected ecosystem helps bridge discovery, development, validation, and clinical implementation. One HALO ecosystem. From life science discovery to clinical deployment.